A lmost 15% of the adult population in the United States has chronic kidney disease (CKD).
A lmost 15% of the adult population in the United States has chronic kidney disease (CKD). 1 Studies indicate that more of these patients will die of cardiovascular diseases (CVD) than will progress to end-stage renal disease. 2 Renal dysfunction promotes a process of accelerated atherosclerosis 3 and abnormalities in lipoprotein morphology and metabolism that are unique to CKD. 4 The increased CVD risk in CKD is well established, 5 and clinical practice guidelines 6 advise using statins to reduce this risk. Statins target low-density lipoprotein cholesterol and have long been the cornerstone of atherosclerotic CVD prevention in the general population. 7 However, in people with CKD, there still remains a substantial risk for CVD even after treatment with statins. 8 Further, studies have failed to show the same association between elevated low-density lipoprotein cholesterol and increased risk for CVD in the setting of CKD 9 as is seen in non-CKD people. Herein lies a potential opportunity for greater CVD risk reduction in CKD by determining the role of therapeutic targets other than low-density lipoprotein cholesterol.
Lipoprotein(a) [Lp(a)] is a modified low-density lipoprotein particle covalently linked to apolipoprotein(a). 10, 11 Elevated Lp(a) is an independent and causal risk factor for atherosclerotic CVD in the general population [12] [13] [14] and is found in increased levels in CKD. 15 Plasma levels of Lp(a) are highly genetically determined, primarily by variants at the LPA gene locus located on chromosome 6q26-q27. [16] [17] [18] Prior studies have shown that the rs10455872 and rs3798220 single nucleotide polymorphisms (SNPs) at this locus are strongly associated with Lp(a) level, as well as increased risk for coronary artery disease. [19] [20] [21] In the Jackson Heart Study, 22 another SNP at the LPA locus, rs9457951, was associated with a 25% increase in Lp(a) level per variant allele. Renal dysfunction is one of the few environmental factors that affects Lp(a) levels. 23 And, while studies have suggested that elevated Lp(a) levels are associated with the increased risk for atherosclerotic CVD events seen in those on hemodialysis, 12, 24, 25 the quantitative impact of Lp(a) on CVD risk in the population with nondialysis-dependent CKD remains less clear. Determining the role of elevated Lp(a) in this setting may guide the future direction of CVD prevention in CKD as emerging agents, such as PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors 26 and apolipoprotein(a) antisense oligonucleotides, 27 have been shown to lower Lp(a). The primary objectives of this study were to (1) determine the association between LPA variants and Lp(a) level in people with CKD, (2) determine the association between baseline renal function and Lp(a) level in people with CKD, (3) determine the interaction between these SNPs and renal function on Lp(a) level, and (4) relate baseline Lp(a) levels to myocardial infarction (MI) and death in this setting.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Of the 3939 CRIC (Chronic Renal Insufficiency Cohort) participants, the 3744 participants with available baseline Lp(a) levels were divided into quartiles: the first quartile was Lp(a) levels <9.8 mg/dL, the second quartile was Lp(a) levels of 9.8 to 26.0 mg/dL, the third quartile was Lp(a) levels of 26.1 to 61.3 mg/dL, and the fourth quartile was Lp(a) levels >61.3 mg/dL. Baseline characteristics for each quartile are described in Table 1 . The mean age of the study cohort was 58 years; 54.7% were male, and 41.1% were non-Hispanic White.
Association of LPA Variants and Renal Function With Lp(a) Level
There were 3464 participants from the study cohort who also had genotype data for the rs10455872 SNP and 3459 participants with genotype data for the rs6930542 SNP, which was used as a proxy for the rs9457951 SNP (Table I in In the adjusted linear regression model, the presence of at least 1 minor allele copy of rs10455872 was associated with a 1.51 (95% confidence interval [CI], 1.37-1.65) times higher log-transformed Lp(a) level (Table III in the onlineonly Data Supplement). Using reverse log transformation, this is equivalent to a 353% higher average Lp(a) level for carriers compared with noncarriers of the SNP. Similarly, carriers of the rs6930542 variant were associated with a 0.43 (95% CI, 0.32-0.55) times higher log-transformed Lp(a) level than noncarriers-equivalent to a 54% higher average Lp(a). In analysis of the association of baseline renal function with baseline Lp(a) level, those with eGFR values lower than 45 mL/min per 1.73 m 2 had a 16% higher average Lp(a) level compared with those with higher eGFR, after adjusting for covariates. Testing for the interaction between each of the rs10455872 and rs6930542 SNPs and the binary eGFR variable was not significant (P=0.57 and 0.50, respectively).
Association of Lp(a) Levels With Clinical Outcomes
Over a median follow-up period of 7.5 years, 315 participants experienced an MI, and there was a total of 822 deaths. For all events and the composite end point, event rates differed significantly among the quartiles of Lp(a) ( Table 3 ). The second quartile had the lowest event rate for all end points and was used as the reference quartile in the survival analyses. Kaplan-Meier time-to-event curves for the composite end point (MI or death) are shown in Figure 2 . Hazard ratios (HRs) with 95% CIs per quartile for each end point are summarized in Table 4 . After adjusting for covariates, the third and fourth quartiles of Lp(a) were significantly associated with MI (HR, 1.45; 95% CI, 1.03-2.05; P=0.03 and HR, 1.49; Proteinuria was found to be a significant effect modifier on the association between elevated Lp(a) and the composite outcome of MI or death (P value for interaction =0.02; Figure  I in the online-only Data Supplement). When stratifying by baseline 24-hour urine protein excretion, the HR for the fourth quartile was 1.62 (95% CI, 1.24-2.12) for those with urine protein <0.5 g/24 h and 0.88 (95% CI, 0.66-1.17) for those with urine protein ≥0.5 g/24 h.
In sensitivity analyses, 1045 participants with a history of CVD were excluded, leaving 2699 participants for analyses. There were 152 incident MI cases and a total of 511 events (incident MI or death). Among this subset of participants, elevated Lp(a) was not found to be significantly associated with incident MI (HR, 1.46; 95% CI, 0.88-2.41; P=0.14 for the fourth quartile compared with the second quartile). However, the highest quartile of Lp(a) was associated with a 33% higher rate of death (HR, 1.33; 95% CI, 1.00-1.77; P=0.049) and a 36% higher rate of the composite outcome (HR, 1.36; 95% CI, 1.04-1.76; P=0.02) compared with the second quartile.
Discussion
This study evaluates the relationship between SNPs at the LPA locus and renal function with plasma Lp(a) level and offers substantive evidence for the association between elevated Lp(a) and adverse outcomes in a large and diverse cohort of people with CKD. This study showed that the rs10455872 variant and the rs6930542 variant (as a proxy for the rs9457951 SNP) are each independently associated with Lp(a) level in this population with CKD, expanding on the findings of previous studies that have shown this association in the non-CKD setting. 19, 22 Findings from the analyses also showed that with increasing severity of renal disease at baseline, Lp(a) levels were progressively higher. There appeared to be a compounding effect between the variants and renal function, resulting in higher Lp(a) levels for LPA variant carriers with more progressive renal disease compared with those with more preserved renal function.
The median Lp(a) level of 126 634 participants in a 2009 meta-analysis by the Emerging Risk Factors Collaboration 14 was 12.6 mg/dL (IQR, 4.9-32.1 mg/dL), revealing the general range of Lp(a) levels in the wider population. In comparison, the median level in the CRIC population was 26 mg/dL (IQR, 9.8-61.3 mg/dL). The study authors of the meta-analysis noted a 2-fold higher median level in Blacks compared with Whites, but the median Lp(a) level of 14.1 mg/dL (IQR, 6.4-37.3 mg/ dL) among the non-Hispanic Whites (n=1540) in the CRIC population is still higher than that for the combined population in the meta-analysis. In the MESA (Multi-Ethnic Study of Atherosclerosis), 28 a United States-based cohort of over 6000 adults free from CVD at baseline, the reported median Lp(a) level in the 1347 Black participants was 35.1 mg/dL (IQR, 20.4-61.6 mg/dL), which is lower than the median of 45.4 mg/dL (IQR, 23.8-79.3 mg/dL) in the 1608 non-Hispanic Blacks in the CRIC population. It is unclear why Lp(a) levels are elevated in the setting of CKD but is thought to be because of decreased renal clearance. 15 In the analysis of 66 renal transplant recipients and 31 hemodialysis patients at one institution, Rosas et al 29 found that Lp(a) levels did not change after initiation of hemodialysis but decreased significantly after renal transplant. While other studies have also shown that Lp(a) levels are elevated in the setting of CKD, 10, 15 published data on the relationship between Lp(a) and CVD outcomes in CKD are both limited and variable in their conclusions. In a study published in 2005, Shlipak et al 30 evaluated risk factors for death caused by CVD in 5808 participants from the Cardiovascular Health Study followed for a mean of 8.6 years. In the 1249 participants with CKD, the study authors found that the highest quartile of Lp(a), compared with the lower 3 quartiles, was not significantly associated with cardiovascular mortality (HR, 1.20; 95% CI, 0.93-1.54). Notably, the CKD patients were much older than the CRIC population (mean age 75 versus 58 years). In a 2015 study from Japan, Konishi et al 31 reported on the association between Lp(a) level and poor outcomes (death and acute coronary syndrome) in 904 CKD patients who underwent percutaneous coronary intervention at a single institution in Japan. The study authors found an increased risk for outcomes in those with Lp(a) levels above the median compared with those below (HR, 1.35; 95% CI, 1.01-1.82).
Results from our study indicate a strong and substantial increase in events and outcomes in CKD with the presence of elevated Lp(a). After using a multivariable-adjusted model, the upper 2 quartiles of the CRIC cohort (with Lp(a) >26 mg/dL) experienced a 45% and 49% higher risk of MI, respectively, compared with those with a lower Lp(a) level. And, those in the uppermost quartile of Lp(a) level had a 28% higher risk of death. The association between elevated Lp(a) and outcomes seen in the CRIC population seem to be higher than the associations reported in the wider population. In the meta-analysis by the Emerging Risk Factors Collaboration, 14 the study authors reported an adjusted summary relative risk of 1.27 (95% CI, 1.17-1.38) for coronary heart disease for those in the top third of Lp(a) levels compared with those in the bottom third.
This study was not powered to measure an association between the LPA variants and the outcomes. For the 243 carriers of the rs10455872 variant, there were only 69 composite events. The event rate (per 1000 person-years) for carriers versus noncarriers (P=0.45) of this variant was 44.7 (95% CI, 35.5-56.6) versus 40.8 (95% CI, 38.2-43.5). For the 517 carriers of the rs6930542, there were 156 total composite events, and the event rate for carriers versus noncarriers (P=0.04) was 48.0 (95% CI, 41.0-56.2) versus 39.9 (95% CI, 37.2-42.8). In a 2009 study, by meta-analyzing genotype data from multiple sources, Clarke et al 19 showed that with a genotype score involving both the rs10455872 and rs3798220 variants, the odds of coronary disease were 1.5× higher with the presence of one variant and over 2.5× higher with the presence of ≥2 variants. In contrast, while the rs9457951 SNP, for which we used rs6930542 as a proxy, was shown to be associated with elevated Lp(a) in the Jackson Heart Study, 22 study investigators did not find an association with incident coronary heart disease in replication analyses using the ARIC Study (Atherosclerosis Risk in Communities).
In the CRIC population, it was the second quartile of Lp(a), and not the first, that experienced the lowest event rates. Notably, those in the lowest quartile (Lp(a) <9.8 mg/dL) had the highest baseline triglyceride levels (142 [IQR, 97-221] mg/dL). It is conceivable that there is a subgroup with low Lp(a) levels for whom elevated triglyceride levels served as the driving factor for the higher event rates observed. This should be further explored in future studies of people with CKD and those with low levels of Lp(a).
Strengths and Limitations
This study has several strengths. The CRIC Study cohort is a large diverse group of people with a range of renal dysfunction at baseline. There is a low participant dropout rate (<2% per year) and lengthy follow-up period. The detailed collection of baseline covariate information allowed for robust multivariate analyses and subgroup analyses. Furthermore, the availability of genotype data on the CRIC participants is a unique resource to examine genetic risk factors in the CKD population. The large number of both Whites and Blacks allowed an analysis of 2 LPA SNPs that appear in vastly different frequencies in these races. Carriers of the rs10455872 SNP, which has been primarily found in Whites with European ancestry, with studies estimating that this variant is present in 7% to 15% of the general population of Europeans, 19, 32 were 77% non-Hispanic White in this study. Similarly, carriers of the rs6930542 SNP were 95% non-Hispanic Black in the CRIC population, consistent with studies that have shown that the rs9457951 SNP is primarily associated with Blacks with a reported minor allele frequency of 0.19 in the Jackson Heart Study. 22 This study is not without limitations. First, the crosssectional analysis of baseline data in this study suggests that with increasing levels of renal insufficiency, there are increasing levels of Lp(a), but causality cannot be concluded from this analysis. Repeated measurements of Lp(a) were not collected in the CRIC study. A longitudinal analysis of Lp(a) levels over time in those with worsening renal function may offer insight into the biology of the Lp(a) elevation seen in CKD. Second, while results suggest an additive effect of LPA variants and renal dysfunction on Lp(a) level, future studies evaluating the impact of these SNPs and renal function in a cohort of people with and without CKD could determine the relative contribution of renal dysfunction to Lp(a) level and whether the strength of the association between elevated Lp(a) and CVD differs among these 2 groups. Third, while the association between elevated Lp(a) and all-cause mortality found in this study is likely driven by a high proportion of CVD-related deaths in CKD, 33, 34 cause of death was not known at the time of this study. Fourth, renal dysfunction may drive CVD risk through pathways 35 other than Lp(a) elevation. When the hazards model was additionally adjusted for eGFR and urine protein excretion, the third quartile of Lp(a) remained significantly associated with MI (HR, 1.43; 95% CI, 1.01-2.03; P=0.046); all other associations were not statistically significant. However, the inclusion of these parameters may represent an overadjustment because renal impairment is likely on the causal pathway for the elevated Lp(a) seen in CKD.
Conclusions
The high burden of CVD in the CKD population, and the unique nature of dyslipidemia and atherosclerosis in this setting, 4 demands novel avenues beyond statins to reduce the risk for MI and other atherosclerotic diseases in this population. In genomic analyses using several large data sources, 36 genetically lower levels of Lp(a) have been shown to be associated with a reduction in not only coronary disease but also in peripheral vascular disease, stroke, and aortic stenosis. This study offers convincing evidence that the elevated Lp(a) seen in CKD could, thus, be an effective target to reduce risk for CVD and these associated disorders in this high-risk population. Future studies evaluating Lp(a) reduction, such as with PCSK9 inhibitors, apolipoprotein(a) antisense oligonucleotides, or other emerging therapeutics, in people with CKD are warranted.
